Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis

被引:6
|
作者
Tada, Yuko [1 ]
Tachibana, Atsushi [1 ]
Heidary, Shahriar [1 ]
Yang, Phillip C. [1 ]
McConnell, Michael, V [1 ]
Dash, Rajesh [1 ]
机构
[1] Stanford Univ, Dept Med Cardiovasc Med, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA
关键词
Ferumoxytol; CMR; MRI; Myocarditis; T2*map; IRON-OXIDE; ENDOMYOCARDIAL BIOPSY; INVERSION-RECOVERY; HEART-FAILURE; DIAGNOSIS; PARTICLES; CELLS; DEATH; MRI; SUPPRESSION;
D O I
10.1186/s12968-019-0587-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The diagnostic utility of cardiovascular magnetic resonance (CMR) is limited during the early stages of myocarditis. This study examined whether ferumoxytol-enhanced CMR (FE-CMR) could detect an earlier stage of acute myocarditis compared to gadolinium-enhanced CMR. Methods Lewis rats were induced to develop autoimmune myocarditis. CMR (3 T, GE Signa) was performed at the early- (day 14, n = 7) and the peak-phase (day 21, n = 8) of myocardial inflammation. FE-CMR was evaluated as % myocardial dephasing signal loss on gradient echo images at 6 and 24 h (6 h- & 24 h-FE-CMR) following the administration of ferumoxytol (300 mu molFe/kg). Pre- and post-contrast T2* mapping was also performed. Early (EGE) and late (LGE) gadolinium enhancement was obtained after the administration of gadolinium-DTPA (0.5 mmol/kg) on day 14 and 21. Healthy rats were used as control (n = 6). Results Left ventricular ejection fraction (LVEF) was preserved at day 14 with inflammatory cells but no fibrosis seen on histology. EGE and LGE at day 14 both showed limited myocardial enhancement (EGE: 11.7 +/- 15.5%; LGE: 8.7 +/- 8.7%; both p = ns vs. controls). In contrast, 6 h-FE-CMR detected extensive myocardial signal loss (33.2 +/- 15.0%, p = 0.02 vs. EGE and p < 0.01 vs. LGE). At day 21, LVEF became significantly decreased (47.4 +/- 16.4% vs control: 66.2 +/- 6.1%, p < 0.01) with now extensive myocardial involvement detected on EGE, LGE, and 6 h-FE-CMR (41.6 +/- 18.2% of LV). T2* mapping also detected myocardial uptake of ferumoxytol both at day 14 (6 h R2* = 299 +/- 112 s(- 1)vs control: 125 +/- 26 s(- 1), p < 0.01) and day 21 (564 +/- 562 s(- 1), p < 0.01 vs control). Notably, the myocardium at peak-phase myocarditis also showed significantly higher pre-contrast T2* (27 +/- 5 ms vs control: 16 +/- 1 ms, p < 0.001), and the extent of myocardial necrosis had a strong positive correlation with T2* (r = 0.86, p < 0.001). Conclusions FE-CMR acquired at 6 h enhance detection of early stages of myocarditis before development of necrosis or fibrosis, which could potentially enable appropriate therapeutic intervention.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis
    Yuko Tada
    Atsushi Tachibana
    Shahriar Heidary
    Phillip C. Yang
    Michael V. McConnell
    Rajesh Dash
    Journal of Cardiovascular Magnetic Resonance, 21
  • [2] Ferumoxytol-enhanced magnetic resonance imaging in acute myocarditis
    Stirrat, Colin G.
    Alam, Shirjel R.
    MacGillivray, Thomas J.
    Gray, Calum D.
    Dweck, Marc R.
    Dibb, Kevin
    Spath, Nick
    Payne, John R.
    Prasad, Sanjay K.
    Gardner, Roy S.
    Mirsadraee, Saeed
    Henriksen, Peter A.
    Semple, Scott I. K.
    Newby, David E.
    HEART, 2018, 104 (04) : 300 - 305
  • [3] Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD
    Mukundan, Srinivasan
    Steigner, Michael L.
    Hsiao, Li-Li
    Malek, Sayeed K.
    Tullius, Stefan G.
    Chin, Matthew S.
    Siedlecki, Andrew M.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 67 (06) : 984 - 988
  • [4] Ferumoxytol-enhanced vascular suppression in magnetic resonance neurography
    Queler, Sophie C.
    Tan, Ek Tsoon
    Geannette, Christian
    Prince, Martin
    Sneag, Darryl B.
    SKELETAL RADIOLOGY, 2021, 50 (11) : 2255 - 2266
  • [5] Ferumoxytol-enhanced vascular suppression in magnetic resonance neurography
    Sophie C. Queler
    Ek Tsoon Tan
    Christian Geannette
    Martin Prince
    Darryl B. Sneag
    Skeletal Radiology, 2021, 50 : 2255 - 2266
  • [6] Vascular applications of ferumoxytol-enhanced magnetic resonance imaging of the abdomen and pelvis
    Andrew W. Bowman
    Cory R. Gooch
    Lauren F. Alexander
    Madhura A. Desai
    Candice W. Bolan
    Abdominal Radiology, 2021, 46 : 2203 - 2218
  • [7] Vascular applications of ferumoxytol-enhanced magnetic resonance imaging of the abdomen and pelvis
    Bowman, Andrew W.
    Gooch, Cory R.
    Alexander, Lauren F.
    Desai, Madhura A.
    Bolan, Candice W.
    ABDOMINAL RADIOLOGY, 2021, 46 (05) : 2203 - 2218
  • [8] Intraluminal Assessment of Coronary Arteries With Ferumoxytol-Enhanced Magnetic Resonance Angiography
    Chin, Matthew S.
    Steigner, Michael
    Yin, Wenqing
    Kwong, Raymond Y.
    Siedlecki, Andrew M.
    JACC-CARDIOVASCULAR IMAGING, 2018, 11 (03) : 505 - 508
  • [9] Ferumoxytol-enhanced Magnetic Resonance Angiography (FeMRA) - optimal dosing and feasibility
    Vesey, A.
    BRITISH JOURNAL OF SURGERY, 2017, 104 : 12 - 12
  • [10] Ferumoxytol-Enhanced Magnetic Resonance Angiography-Clinical Feasibility and Optimal Dosing
    Vesey, Alex
    Hennessy, Martin
    Stoumpos, Sokratis
    Radjenovic, Aleksandra
    Kingsmore, David
    Mark, Patrick
    Roditi, Giles
    JOURNAL OF VASCULAR SURGERY, 2018, 68 (05) : E163 - E163